Filtered By:
Specialty: Cancer & Oncology
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 187 results found since Jan 2013.

Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer.
CONCLUSION: Our study demonstrates widespread use of bevacizumab among patients who had contraindications. Black patients were less likely to receive the drug, but those who did were more likely to have a contraindication. Efforts to understand toxicity and efficacy in populations excluded from clinical trials are needed. PMID: 24002522 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - September 3, 2013 Category: Cancer & Oncology Authors: Hershman DL, Wright JD, Lim E, Buono DL, Tsai WY, Neugut AI Tags: J Clin Oncol Source Type: research

Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer Health Services and Outcomes
Conclusion Our study demonstrates widespread use of bevacizumab among patients who had contraindications. Black patients were less likely to receive the drug, but those who did were more likely to have a contraindication. Efforts to understand toxicity and efficacy in populations excluded from clinical trials are needed.
Source: Journal of Clinical Oncology - September 27, 2013 Category: Cancer & Oncology Authors: Hershman, Wright, Lim, Buono, Tsai, Neugut Tags: Quality of Care, Quality of Care Health Services and Outcomes Source Type: research

432p * patterns and efficacy of bevacizumab use across treatment lines in glioblastoma
Conclusions: Our results show bevacizumab treatment may be more efficient after a recurrence than when used in the beginning of treatment and are in line with reported registration trials data.Disclosure: All authors have declared no conflicts of interest.
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Azam, M. B., Rho, Y. S., Mamo, A., Sahebjam, S., Muanza, T., Guiot, M., Al-Shami, J., Sharma, R., Kavan, P. Tags: CNS tumours Source Type: research

1497p * lessons from the past: long-term safety and efficacy outcomes of a prematurely terminated, randomized phase iii trial of precautionary versus hemoglobin-based erythropoietin administration for chemotherapy-associated anemia in patients with solid tumors
Conclusions: Prophylactic administration of ESA for CIA in patients with solid tumors was associated with increased incidence of a composite of thrombosis-related adverse events, especially in patients receiving adjuvant treatment, but did not have a detrimental impact on relapse/progression and survival rates.Disclosure: All authors have declared no conflicts of interest.
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Mountzios, G., Aravantinos, G., Kouvatseas, G., Karina, M., Samantas, E., Papakostas, P., Skarlos, D., Galani, E., Kalofonos, H., Makatsoris, T., Bafaloukos, D., Pectasides, D. G., Fountzilas, G. Tags: supportive care Source Type: research

Venous thromboembolism in children with acute lymphoblastic leukemia
Abstract Venous thromboembolism (VTE) occurs in 0.95–36 % of children with acute lymphoblastic leukemia almost exclusively during chemotherapy. It is most commonly associated with concurrent l-asparaginase and steroid therapy, central venous line use, and inherited thrombophilia. Clinical manifestations regarding the location of VTE include central nervous system thrombosis (sinus venous thrombosis, cerebral infarct/stroke), upper-/lower-limb deep venous thrombosis, pulmonary embolism, and right atrial/intracardiac and superficial venous thrombosis and can be both symptomatic and asymptomatic. The majority of ...
Source: Memo - Magazine of European Medical Oncology - September 1, 2014 Category: Cancer & Oncology Source Type: research

Risk factors for venous thromboembolism in patients undergoing craniotomy for neoplastic disease
Abstract Patients undergoing neurosurgical procedures for neoplasia have historically been considered at higher risk for developing venous thromboembolism (VTE). We sought to identify risk factors associated with VTE in patients undergoing craniotomy for tumor resection. We reviewed a national surgical quality database (American College of Surgeons National Surgical Quality Improvement Project, ACS-NSQIP, http://site.acsnsqip.org/). Patients undergoing non-emergent craniotomy for neoplastic indications were identified based on current procedural terminology codes. Clinical factors were identified that were associ...
Source: Journal of Neuro-Oncology - November 19, 2014 Category: Cancer & Oncology Source Type: research

Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage
Publication date: January 2015 Source:Acta Pharmaceutica Sinica B, Volume 5, Issue 1 Author(s): Kai Sun , Jingyu Fan , Jingyan Han Ischemic stroke and ischemia/reperfusion (I/R) injury induced by thrombolytic therapy are conditions with high mortality and serious long-term physical and cognitive disabilities. They have a major impact on global public health. These disorders are associated with multiple insults to the cerebral microcirculation, including reactive oxygen species (ROS) overproduction, leukocyte adhesion and infiltration, brain blood barrier (BBB) disruption, and capillary hypoperfusion, ultimately resulting...
Source: Acta Pharmaceutica Sinica B - January 25, 2015 Category: Cancer & Oncology Source Type: research

Abstract 5267: Comorbidity and cause of death in patients with chronic lymphocytic leukemia (CLL)
Conclusions. Despite the advanced age at CLL diagnosis, the frequent presence of comorbidities, and the indolent nature of the disease, CLL progression is the ultimate cause of death in 51% of newly diagnosed CLL patients, with an additional 26% dying of causes potentially related to CLL, such as infections and second cancers. The influence of comorbidities and other clinical factors at diagnosis (e.g. smoking, Charlson Comorbidity Index) on survival and ultimate cause of death are being abstracted, and will be presented at the meeting.Citation Format: Paolo Strati, Kari Chaffe, Sara Achenbach, Timothy Call, Neil Kay, Jame...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Strati, P., Chaffe, K., Achenbach, S., Call, T., Kay, N., Cerhan, J., Slager, S., Shanafelt, T. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research

Update on Breast Cancer Risk Reduction Therapy
Abstract In women at increased risk of breast cancer age ≥35 years, the selective estrogen receptor modulator (SERM) tamoxifen should be discussed as an option to reduce the risk of estrogen receptor (ER)-positive breast cancer. In postmenopausal women, raloxifene, anastrozole, and exemestane should also be discussed as options for breast cancer risk reduction. Risk reduction with SERMs continues for at least 10 years in both premenopausal and postmenopausal women. Tamoxifen is not recommended for women with a history of deep vein thrombosis, pulmonary embolus, stroke, transient ischemic attack, or during prol...
Source: Current Breast Cancer Reports - July 19, 2016 Category: Cancer & Oncology Source Type: research

P08.46 Rechallenge with bevacizumab in a long-term survivor with glioblastoma
The prognosis of patients with glioblastoma multiforme (GBM, WHO grade IV), the most common primary brain tumor in adults, is generally poor with median survival of less than one year in untreated patients and approximately 15 months following standard of care therapy. However, 10 % survival at 5 years was observed in a randomized phase III study. At GBM recurrence, the addition of bevacizumab (BEV), a humanized monoclonal antibody against circulating vascular endothelial growth factor (VEGF), resulted in a 3–4 month prolongation of progression-free survival (PFS) without improving overall survival (OS...
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Koeppen, S., Hense, J. Tags: P08 Glioblastom and Anaplastic gliomas Source Type: research

The clinical presentation and genotype of protein C deficiency with double mutations of the protein C gene
ConclusionsThe genotype of double‐PROC mutants might show less diversity than heterozygous mutants in terms of the timing of the onset of thrombophilia (newborn onset or late onset).
Source: Pediatric Blood and Cancer - January 22, 2017 Category: Cancer & Oncology Authors: Hirofumi Inoue, Shin ‐ichi Terachi, Takeshi Uchiumi, Tetsuji Sato, Michiyo Urata, Masataka Ishimura, Yui Koga, Taeko Hotta, Toshiro Hara, Dongchon Kang, Shouichi Ohga Tags: Research Article Source Type: research

Abstract P2-01-23: Long-term follow-up of persistent breast dermopigmentation after sentinel lymph node identification using superparamagnetic iron oxide particles (SIENNA+(R))
Patients with breast cancer (BC) and those at high risk for BC are often reluctant to initiate Tamoxifen (Tam) due to potential adverse events (AEs) such as deep vein thrombosis (DVT), pulmonary embolus (PE), acute ischemic stroke (AIS), myocardial infarction (MI) and endometrial cancer (EC). Some decline this life saving therapy due to fear of AEs. AE rates from RCTs are low, but AE rates in the general population are not well documented.Methods: The MarketScanR database (2010-2013) was searched for patients aged 30-64 with a prescription of Tam active for more than 120 days. Patients with prior DVT, PE, AIS, MI or EC wer...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: K Hannebicque, L Boulanger, E Bogart, S Giard, MP Chauvet, JL Houpeau Tags: Poster Session Abstracts Source Type: research

Use and Misuse of Aspirin in Primary Cardiovascular Prevention.
Abstract The use of low-dose aspirin in primary prevention of cardiovascular (CV) events in healthy or apparently healthy people is a widely debated topic. Many arguments indicate that "primary prevention" is only a conventional definition and that the transition from primary to secondary prevention represents a continuum of increasing levels of CV risk. Although there are no direct proofs of a different efficacy of aspirin at different CV risk levels, in low-risk populations aspirin will appear to be less efficient. In fact, the lower number of events occurring in patients at low risk yields lower absolute number...
Source: Clinical Colorectal Cancer - May 6, 2017 Category: Cancer & Oncology Authors: Coccheri S Tags: Clin Med Insights Cardiol Source Type: research

Short - Term Risk of Arterial Embolism Up in Cancer Patients
Increased risk of arterial thromboembolism, MI, ischemic stroke for cancer patients
Source: The Doctors Lounge - Oncology - August 15, 2017 Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Internal Medicine, Critical Care, Emergency Medicine, Neurology, Oncology, Journal, Source Type: news

Active Expression of Human Tissue Plasminogen Activator (t-PA) c-DNA from Pulmonary Metastases in the Methylotrophic Yeast Pichia Pastoris KM71H Strain
Conclusions: Correspondingly, Pichia pastoris KM71H is an appropriate strain for production of active recombinant protein. PMID: 28843264 [PubMed - as supplied by publisher]
Source: Asian Pacific Journal of Cancer Prevention - August 29, 2017 Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research